Le Lézard
Classified in: Health
Subjects: PDT, ANW

Watchfrog Laboratory validates a new method to identify endocrine disruptors


EVRY, France, July 7, 2022 /PRNewswire/ -- The member countries of the Organisation for Economic Co-operation and Development (OECD) have adopted a new test method, Test Guideline n°251 (TG n°251), which contributes to testing strategies for identifying endocrine disrupting chemicals.

Watchfrog© Fish embryo. Fluorescence in the kidneys reveals the action of androgen disruptors.

The RADAR assay TG n°251 (Rapid Androgen Disruption Activity Reporter) contributes to the goal of identifying chemicals which could disrupt signaling by androgenic hormones. Androgens are steroid hormones that are essential for the development of male characteristics, they are also synthesised by women to produce estrogen and participate in many functions for men and women. Disrupting this hormonal balance could lead to infertility, developmental disorders, disrupted menstrual cycle and even tumors.

This method, invented at Watchfrog Laboratory (Genopole Evry, France), a spin-off from the CNRS - National Museum of Natural History, is the second method from the French laboratory to be validated at the international level. The validation of this assay involved many laboratories in different continents and, with the support of British and French organisations (DEFRA, Public Health UK and INERIS), the protocol has been approved by OECD experts. The publication by the OECD of this Test Guideline is a significant step in strengthening the available tools for applying European criteria for identifying Endocrine Disruptors, while reducing animal experimentation.

"There was a need to develop faster and more accessible tests to assess the large number of chemicals used in Europe. This test method harnesses the ethical advantages from in vitro stages of aquatic larvae while providing a large weight of evidence for any endocrine effects on sensitive embryonic stages of early development" explains Gregory Lemkine, Watchfrog CEO. Contributing to replace tests on mammals and reduce animal suffering, RADAR will also enable a significant reduction in the cost to industry when performing chemical risk assessment. 

The RADAR assay reveals the capacity of a chemical to induce a key physiological event related specifically to the criterion of androgen disruption. Other tests, following the same approach and covering other important hormonal pathways are already in use: the REACTIV test for estrogens and the XETA test for thyroid hormones. The thyroid assay XETA, validated in 2019 as an OECD test guideline (OECD TG n°248) has been used to assess many active chemicals in plant protection products and biocides, making Watchfrog the first French laboratory to validate its tools at international level.

Now published, TG n°251 is available through a network of distributing labs progressively adopting the RADAR method.

Photo: https://mma.prnewswire.com/media/1854414/Watchfrog_Fish_Embryo.jpg


These press releases may also interest you

at 07:30
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown Magnificent Mile on June 21?22, 2024. This biennial...

at 07:30
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF1, used...

at 07:30
The American Trucking Associations is calling attention to the negative consequences for highway safety and safety-sensitive industries that could result from the U.S. Drug Enforcement Administration's proposal to reschedule marijuana from a Schedule...

at 07:30
-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)-    Data to be presented from...

at 07:28
We are advised by OsteoStrong that journalists and other readers should disregard the news release, OsteoStrong Celebrates Success and Innovation at 11th Annual Global Franchise Owner Convention, issued May 9, 2024 over PR Newswire. SOURCE...

at 07:05
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...



News published on and distributed by: